Loading...

FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640905 25 tests $83
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests $194
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests $405
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining

  1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
  2. Transfer 100 µL of cell suspension in 5 mL test tube.
  3. Add 5 µL of fluorochrome conjugated Annexin V.
  4. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired.
  5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
  6. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step.
  7. Analyze by flow cytometry.

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  2. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  3. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  4. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  5. Glynn RA, et al. 2022. J Immunol. 208:371. PubMed
  6. Cao H, et al. 2022. Br J Haematol. 198:155. PubMed
  7. Ugamraj HS, et al. 2022. MAbs. 14:2095949. PubMed
  8. Cao L, et al. 2022. Cell Rep. 40:111156. PubMed
  9. Choi UY, et al. 2022. Cell Rep. 40:111234. PubMed
  10. Kimmerling RJ, et al. 2022. Commun Biol. 5:1295. PubMed
  11. Chen X, et al. 2022. Front Pharmacol. 13:1028692. PubMed
  12. Shahid AM, et al. 2022. PLoS One. 17:e0278209. PubMed
  13. Önel T, et al. 2023. Naunyn Schmiedebergs Arch Pharmacol. :. PubMed
  14. Papakonstantinou A, et al. 2022. Int J Mol Sci. 24: . PubMed
  15. Li J, et al. 2023. J Biol Chem. 299:102875. PubMed
  16. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  17. Tay HG, et al. 2023. Mol Ther. 31:825. PubMed
  18. Dean BD, et al. 2023. J Immunother Cancer. 11: . PubMed
  19. Lieschke E, et al. 2022. Cell Death Differ. 29:1004. PubMed
  20. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  21. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  22. Gallego-Murillo JS, et al. 2022. Biotechnol Bioeng. 119:3096. PubMed
  23. Du X, et al. 2023. Nucleic Acids Res. 51:1050. PubMed
  24. Vanoli F, et al. 2023. Oncogenesis. 12:8. PubMed
  25. Lei K, et al. 2023. iScience. 26:106001. PubMed
  26. Ohuchi K, et al. 2023. Biomed Rep. 18:28. PubMed
  27. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  28. Perez GI, et al. 2023. Vaccines (Basel). 11:. PubMed
  29. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  30. Potez M, et al. 2023. Front Oncol. 13:1124272. PubMed
  31. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  32. Quintela M, et al. 2023. Clin Epigenetics. 15:63. PubMed
  33. Quintela M, et al. 2023. Br J Cancer. . PubMed
  34. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  35. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  36. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  37. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  38. Kim EH, et al. 2020. Elife. 9:00. PubMed
  39. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  40. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  41. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  42. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  43. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  44. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  45. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  46. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  47. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  48. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  49. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  50. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  51. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  52. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  53. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  54. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  55. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  56. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  57. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  58. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  59. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  60. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  61. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  62. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  63. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  64. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  65. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  66. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  67. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  68. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  69. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  70. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  71. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  72. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  73. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  74. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  75. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  76. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  77. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  78. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  79. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  80. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  81. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  82. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  83. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  84. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  85. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  86. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  87. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  88. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  89. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  90. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  91. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  92. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  93. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  94. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  95. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  96. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  97. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  98. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  99. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  100. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  101. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  102. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  103. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  104. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  105. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  106. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  107. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  108. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  109. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  110. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  111. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  112. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  113. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  114. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  115. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  116. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  117. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  118. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  119. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  120. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  121. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  122. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  123. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  124. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  125. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  126. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  127. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  128. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  129. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  130. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  131. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  132. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  133. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  134. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  135. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  136. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  137. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  138. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  139. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  140. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  141. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  142. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  143. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  144. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  145. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  146. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  147. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  148. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  149. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  150. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  151. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  152. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  153. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  154. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  155. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  156. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  157. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  158. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  159. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  160. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  161. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  162. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  163. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  164. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  165. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  166. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  167. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  168. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  169. Babaei A, et al. 2020. Daru. 28:555. PubMed
  170. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  171. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  172. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  173. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  174. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  175. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  176. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  177. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  178. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  179. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  180. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  181. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  182. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  183. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  184. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  185. Huang YL, et al. 2020. Elife. 9:00. PubMed
  186. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  187. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  188. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  189. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  190. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  191. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  192. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  193. Alcon C, et al. 2021. Cells. 10:. PubMed
  194. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  195. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  196. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  197. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  198. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  199. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  200. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  201. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  202. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  203. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  204. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  205. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  206. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  207. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  208. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  209. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  210. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  211. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  212. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  213. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  214. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  215. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  216. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  217. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  218. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  219. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  220. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  221. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  222. He J, et al. 2017. FASEB J. 31:2893. PubMed
  223. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  224. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  225. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  226. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  227. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  228. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  229. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  230. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  231. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  232. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  233. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  234. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  235. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
  236. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  237. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  238. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  239. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  240. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  241. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  242. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  243. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
Annexin V
Specificity Alt (DOES NOT SHOW ON TDS):
Annexin V
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 7    Revision Date: 10/22/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account